Aduro BioTech (ADRO) Earning Somewhat Favorable Media Coverage, Analysis Finds

News coverage about Aduro BioTech (NASDAQ:ADRO) has trended somewhat positive this week, Accern Sentiment reports. The research group rates the sentiment of news coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Aduro BioTech earned a news impact score of 0.15 on Accern’s scale. Accern also gave media coverage about the biotechnology company an impact score of 45.5082955010034 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

Shares of Aduro BioTech (NASDAQ:ADRO) traded down $0.15 during mid-day trading on Friday, hitting $6.10. 428,900 shares of the stock traded hands, compared to its average volume of 506,966. The stock has a market cap of $483.15, a price-to-earnings ratio of -4.49 and a beta of 3.01. Aduro BioTech has a 1-year low of $5.82 and a 1-year high of $14.05.

Several research firms have issued reports on ADRO. Oppenheimer began coverage on shares of Aduro BioTech in a research note on Monday, October 30th. They set a “buy” rating and a $15.00 price target on the stock. HC Wainwright decreased their price target on shares of Aduro BioTech from $18.00 to $9.50 and set a “buy” rating on the stock in a research note on Wednesday, December 13th. BidaskClub cut shares of Aduro BioTech from a “hold” rating to a “sell” rating in a research note on Saturday, December 9th. Canaccord Genuity set a $30.00 price target on shares of Aduro BioTech and gave the stock a “buy” rating in a research note on Thursday, December 14th. Finally, ValuEngine cut shares of Aduro BioTech from a “sell” rating to a “strong sell” rating in a research note on Friday, February 2nd. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and eight have assigned a buy rating to the company’s stock. Aduro BioTech presently has an average rating of “Buy” and an average price target of $17.71.

In other news, COO Gregory W. Schafer sold 20,000 shares of the stock in a transaction dated Friday, December 1st. The shares were sold at an average price of $9.34, for a total transaction of $186,800.00. Following the transaction, the chief operating officer now directly owns 155,676 shares in the company, valued at approximately $1,454,013.84. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, VP Jennifer Lew sold 6,600 shares of the stock in a transaction dated Friday, December 1st. The stock was sold at an average price of $9.46, for a total transaction of $62,436.00. Following the transaction, the vice president now owns 68,938 shares in the company, valued at $652,153.48. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 172,656 shares of company stock worth $1,486,582. Insiders own 6.60% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Aduro BioTech (ADRO) Earning Somewhat Favorable Media Coverage, Analysis Finds” was originally published by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this report on another website, it was stolen and republished in violation of US and international copyright laws. The legal version of this report can be viewed at https://stocknewstimes.com/2018/02/16/aduro-biotech-adro-earning-somewhat-favorable-media-coverage-analysis-finds.html.

About Aduro BioTech

Aduro Biotech, Inc is an immunotherapy company, which focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases, including cancer. The Company’s product candidates from its Live, Attenuated, Double-Deleted (LADD) Listeria monocytogenes, Stimulator of Interferon Genes Pathway Activator, and B-select monoclonal antibody platforms are designed to stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies, as well as other immunotherapies.

Insider Buying and Selling by Quarter for Aduro BioTech (NASDAQ:ADRO)

Receive News & Ratings for Aduro BioTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro BioTech and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply